Last reviewed · How we verify
Johnson & Johnson — Portfolio Competitive Intelligence Brief
JNJ (NYSE)
46 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Imaavy | NIPOCALIMAB | marketed | Immunology | 2025-01-01 | ||
| Talvey | TALQUETAMAB | marketed | T-cell surface glycoprotein CD3 | Oncology | 2023-01-01 | |
| Bcmaxcd3 | TECLISTAMAB | marketed | CD3, BCMA | Oncology | 2022-01-01 | |
| Abiraterone Acetate | ABIRATERONE | marketed | Oncology | 2021-01-01 | ||
| Rybrevant | AMIVANTAMAB | marketed | EGFR, MET | Oncology | 2021-01-01 | |
| Spravato | ESKETAMINE | marketed | esketamine | Metabolic | 2019-01-01 | |
| Balversa | ERDAFITINIB | marketed | Kinase Inhibitor [EPC] | Fibroblast growth factor receptor 1 | Oncology | 2019-01-01 |
| Erleada | apalutamide | marketed | Androgen receptor | Oncology | 2018-01-01 | |
| Tremfya | GUSELKUMAB | marketed | Interleukin-23 Antagonist [EPC] | p19 subunit of IL-23 | Immunology | 2017-01-01 |
| Yondelis | TRABECTEDIN | marketed | Alkylating Drug [EPC] | Proto-oncogene tyrosine-protein kinase Src | Oncology | 2015-01-01 |
| Darzalex | daratumumab | marketed | Monoclonal antibody | CD38 | Oncology | 2015-01-01 |
| Invokana | CANAGLIFLOZIN | marketed | Sodium-Glucose Cotransporter 2 Inhibitor | Sodium/glucose cotransporter 2 | Metabolic | 2013-01-01 |
Therapeutic area mix
- Oncology · 18
- Neuroscience · 7
- Immunology · 6
- Infectious Disease · 5
- Metabolic · 4
- Pain · 2
- Cardiovascular · 2
- Dermatology · 1
- Other · 1
- Bone · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
- — Risperdal · 10406160 · Formulation · US
- — Risperdal · 10058554 · Method of Use · US
- — Risperdal · 9597402 · Formulation · US
- — Risperdal · 11110093 · Formulation · US
- — Duragesic · 10610523 · Formulation · US
- — Duragesic · 9289387 · Formulation · US
- — Duragesic · 9642797 · Formulation · US
- — Duragesic · 8835460 · Formulation · US
- — Duragesic · 9241935 · Formulation · US
- — Duragesic · 8835459 · Formulation · US
- — Duragesic · 9642844 · Formulation · US
- — Duragesic · 10016403 · Formulation · US
- — Risperdal · 8221778 · Formulation · US
- — Risperdal · 8741327 · Formulation · US
- — Topamax · 8298580 · Formulation · US
- — Topamax · 8663683 · Formulation · US
- — Topamax · 9549940 · Formulation · US
- — Topamax · 10314790 · Formulation · US
- — Topamax · 9622983 · Formulation · US
- — Topamax · 8889191 · Method of Use · US
- — Topamax · 9555004 · Formulation · US
- — Topamax · 8992989 · Formulation · US
- — Topamax · 8877248 · Formulation · US
- — Risperdal · 11013809 · Formulation · US
- — Risperdal · 11712475 · Method of Use · US
- — Risperdal · 10376590 · Method of Use · US
- — Risperdal · 9186413 · Method of Use · US
- — Risperdal · 9180197 · Formulation · US
- — Risperdal · 10010612 · Formulation · US
- — Topamax · 8298576 · Formulation · US
Competitive overlap (companies sharing drug classes)
- · 9 shared drug classes
- Pfizer · 6 shared drug classes
- Bayer · 5 shared drug classes
- AbbVie · 4 shared drug classes
- Pfizer Inc. · 3 shared drug classes
- Bristol-Myers Squibb · 3 shared drug classes
- Merck & Co. · 3 shared drug classes
- Sanofi · 3 shared drug classes
Subscribe to ongoing alerts
Every new pipeline event for Johnson & Johnson:
- Johnson & Johnson pipeline updates — RSS
- Johnson & Johnson pipeline updates — Atom
- Johnson & Johnson pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Johnson & Johnson — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/johnson-johnson. Accessed 2026-05-13.